MedDataX Logo

What Happens in Vegas: PEP to PrEP Opportunities

NCT ID: NCT03775083

Last Updated: 2018-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-01

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational study looking at barriers to care for individuals seeking care, Post Exposure Prophylaxis (PEP) after an actual or perceived exposure to HIV. Following PEP treatment subjects will be asked about there intent to transition to Pre-Exposure Prophylaxis (PrEP) and surveyed about barriers to care or perceptions of care

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to assess the rate of engagement in a PEP to PrEP HIV provider network for those patients presenting following a non-occupational HIV exposure.

The development of a referral network and intensive clinical follow up of PEP patients will result in more patients appropriately initiating PEP, being referred to appropriate follow up, and post exposure transition and maintaining on PrEP (if indicated) at completion of the PEP medications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exposure to Human Immunodeficiency Virus (Event)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

PEP nPEP Post Exposure Prophylaxis non occupational exposure to HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Currently approved medications

subjects will be treated according to current Department of Health and Human Services (DHHS) Center for Disease control and prevention (CDC), Society for Healthcare Epidemiology of American (SHEA guidelines for nPEP

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Actual or perceived non-occupational exposure to HIV, by self report, within 72 hours of enrollment and referred for care
* able and willing to provide informed consent
* available for 12 months of post expoure follow-up Southern Nevada Ryan White defined service area

Exclusion Criteria

* HIV+ at time of screeing via 4th genderation (Antibody/Antigen) testing
* Current PEP and/or PrEP product condrainidications as listed in the medication product insert.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Huntridge Family Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

John Phoenix

Clinical Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Huntridge Family Clinic

Las Vegas, Nevada, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

John (Rob) Phoenix, MSN, APRN

Role: CONTACT

Phone: 702-979-1111

Email: [email protected]

Christina Madison, PharmD

Role: CONTACT

Phone: 702-968-2044

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

John (Rob) Phoenix, APRN

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HFC018001

Identifier Type: -

Identifier Source: org_study_id